MorphoSys Nominates Three New Candidates for Supervisory Board
(Thomson Reuters ONE) -
MorphoSys AG /
MorphoSys Nominates Three New Candidates for Supervisory Board
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) published today its
agenda for the Company's ordinary Annual General Meeting, which will take place
on Friday, May 8, 2015. MorphoSys's Supervisory Board nominated Ms. Wendy
Johnson, Mr. Klaus Kühn and Dr. Frank Morich as candidates to be elected as new
members at the Company's AGM 2015. Ms. Johnson, Mr. Kühn and Dr. Morich will
replace Dr. Walter Blättler, Dr. Daniel Camus and Dr. Geoffrey Vernon.
Dr. Vernon has been a member of MorphoSys AG's Supervisory Board since 1999,
while Dr. Camus and Dr. Blättler joined in 2002 and 2007, respectively.
"We are delighted to be able to present three highly qualified candidates, each
with extensive industry expertise, for MorphoSys's Supervisory Board. The three
new candidates bring to our Board significant experience in pharmaceutical drug
development and commercialization, finance and accounting as well as business
development," commented Dr. Gerald Möller, Chairman of the Supervisory Board of
MorphoSys AG. "On behalf of the Company, I would like to thank Dr. Walter
Blättler, Dr. Daniel Camus and Dr. Geoffrey Vernon for their invaluable support
over many years in establishing MorphoSys as one of the world's leading
therapeutic antibody companies."
Ms. Wendy Johnson currently serves as Managing Director of Gemini Advisors and
Interim Chief Operating Officer and Member of the Board of Directors of AmpliPhi
BioSciences. Previously, she was a venture partner at ProQuest Investments, a
healthcare-focused venture capital firm. She also founded and served as the
President and Chief Executive Officer of Aires Pharmaceuticals. Prior to joining
ProQuest, she served as Senior Vice President, Corporate Development, at
Salmedix Inc., where she was involved in the clinical development of the
company's oncology portfolio including the cancer drug bendamustine. Before her
time at Salmedix she held various senior business and corporate development
positions and served as Assistant Director with the Center for Devices and
Radiological Health at the U.S. Food and Drug Administration. Ms. Johnson holds
an M.B.A. from Loyola University, an M.S. in clinical microbiology from the
Hahnemann Medical School and a B.S. in microbiology from the University of
Maryland.
Mr. Klaus Kühn, former Chief Financial Officer of Bayer AG, has more than 30
years of experience in executive positions, primarily in the chemical and
pharmaceutical industry with a focus on finance and accounting. Before his
appointment as CFO, he served as Head of Finance at Bayer AG and oversaw the
spin-off and subsequent IPO of the group's former Agfa division. Prior to his
time with Bayer, he was Head of Corporate Staff and Head of Finance at Schering
AG. In the biotechnology industry he previously held positions on the
Supervisory Boards of 4SC AG and MediGene AG. He currently holds positions on
the Supervisory Boards of Flossbach von Storch AG and Hella KGaA Hueck & Co. Mr.
Kühn studied Mathematics and Physics at Technical University of Berlin and holds
an M.B.A. in International Business Studies from the University of South
Carolina, Columbia, U.S.A.
Dr. Frank Morich, M.D., Ph.D. was most recently Chief Commercial Officer and
Member of the Board of Directors of Takeda Pharmaceutical Company Ltd., Tokyo,
Japan, as well as Chief Executive Officer of Takeda Pharmaceutical International
GmbH. Previously, he served as Executive Vice President of International
Operations for Americas/Europe at Takeda Pharmaceuticals International, Inc.
Before his time at Takeda, Dr. Morich served as Chief Executive Officer of
NOXXON Pharma AG from and as Chief Executive Officer and member of the Board of
Directors of Innogenetics NV. Between 1982 and 2002 he held various R&D and
senior management positions in the Bayer Group. In 2000, he was appointed member
of the Management Board of Bayer AG and member of the Board of Directors of
Bayer Corp., USA. In 2002, Dr. Morich was elected Chairman of the Board of
Management and Executive Committee for Bayer Healthcare AG. Dr. Morich studied
medicine at the University of Marburg in Germany, specializing in immunology and
oncology.
The full agenda for the Annual General Meeting is available on the Company's
website under www.morphosys.com/agm.
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 90 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates
about MorphoSys, visit http://www.morphosys.com.
HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®), CysDisplay(®), RapMAT(®), arYla(®),
Ylanthia(®) and 100 billion high potentials(®) are registered trademarks of
MorphoSys AG.
Slonomics(®) is a registered trademark of Sloning BioTechnology GmbH, a
subsidiary of MorphoSys AG.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Mario Brkulj
Associate Director Corporate Communications & IR
Alexandra Goller
Manager Corporate Communications & IR
Jessica Rush
Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-404
investors(at)morphosys.com
Media Release (PDF):
http://hugin.info/130295/R/1907403/679395.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via GlobeNewswire
[HUG#1907403]
Unternehmensinformation / Kurzprofil:
Datum: 30.03.2015 - 14:00 Uhr
Sprache: Deutsch
News-ID 382045
Anzahl Zeichen: 8306
contact information:
Town:
Martinsried / Munich
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 272 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys Nominates Three New Candidates for Supervisory Board"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
